What is the appropriate management of delirium in hospitalized adult patients?

Management of Delirium in Hospitalized Adults

Prioritize multicomponent nonpharmacologic interventions as first-line management for all hospitalized adults with delirium, and avoid routine use of antipsychotics including haloperidol, as they do not reduce delirium duration or improve outcomes and may cause harm.

Core Management Strategy

The foundation of delirium management rests on non-pharmacologic, multicomponent interventions rather than medications. This approach significantly reduces delirium incidence (risk ratio 0.57 in randomized trials, 0.47 in observational studies) 1, 2. These bundles consistently outperform single interventions and pharmacologic approaches across all hospital settings.

Essential Nonpharmacologic Components

Implement the following interventions simultaneously:

• Cognitive stimulation: Reorientation strategies, use of clocks and calendars, cognitive exercises
• Sleep optimization: Control light and noise, cluster care activities, protect nighttime sleep cycles, minimize nocturnal interruptions 1, 2
• Early mobilization: Begin mobilization as soon as feasible to reduce both incidence and duration of delirium 1
• Sensory optimization: Enable use of hearing aids and eyeglasses, correct sensory impairments 2
• Sedation minimization: Use daily sedation interruption or maintain light sedation targets in mechanically ventilated patients 1
• Analgesia-first approach: Prioritize pain control before sedation 1

When Pharmacologic Intervention May Be Considered

Medications should only be used for specific, limited indications—not routinely for delirium itself. The evidence is clear that antipsychotics do not reduce delirium duration, mechanical ventilation time, ICU length of stay, or mortality 3, 1, 2, 4.

Specific Scenarios for Short-Term Medication Use:

1. Severe distress from perceptual disturbances (hallucinations, delusions causing significant fear or agitation):

• Consider atypical antipsychotics over haloperidol 3, 1
• Olanzapine: 2.5-5 mg PO/SC, may offer benefit (Level III-C evidence) 3
• Quetiapine: 25 mg PO, may offer benefit, more sedating (Level V-C evidence) 3
• Aripiprazole: 5 mg PO/IM, may offer benefit (Level IV-C evidence) 3

Important caveat: Haloperidol and risperidone have no demonstrable benefit in mild-to-moderate delirium and are not recommended, as they may worsen symptoms 3. By extension, they likely provide no benefit in severe delirium either.

2. Immediate safety risk (patient poses imminent harm to self or others):

• Use lowest effective dose for shortest duration 3
• Start PRN (as-needed) dosing; only use scheduled dosing if symptoms persist 3
• Discontinue immediately when distressing symptoms resolve 2

3. Severe agitation precluding ventilator weaning in ICU:

• Dexmedetomidine infusion preferred over benzodiazepines for sedation in delirious ICU patients (reduces delirium duration) 1, 2
• This is the only pharmacologic intervention with conditional recommendation for delirium treatment in specific circumstances 2

4. Alcohol or benzodiazepine withdrawal delirium:

• Benzodiazepines are first-line for this specific etiology 3
• Midazolam 2.5 mg SC/IV q1h PRN or Lorazepam 1 mg SC/IV 3
• Use lower doses in elderly/frail patients or those with COPD 3

Critical Contraindications and Warnings:

• Do NOT use antipsychotics in patients with QTc prolongation, history of torsades de pointes, or concurrent QT-prolonging medications 1, 4
• Avoid haloperidol in Parkinson's disease or Lewy body dementia (high risk of extrapyramidal side effects) 3
• Benzodiazepines are NOT part of initial delirium management (except for withdrawal syndromes) as they are deliriogenic, increase fall risk, and cause sedation 3
• Do NOT use rivastigmine—it is specifically not recommended and may worsen outcomes 1, 4

Special Considerations

Opioid-associated delirium: Rotate to fentanyl or methadone, or reduce opioid dose by 30-50% 3

Hypoactive delirium without psychosis: Consider methylphenidate for cognitive improvement when no delusions or perceptual disturbances are present 3

ICU-specific risk factors to address: Benzodiazepine use is a risk factor for delirium development; minimize or avoid 1. Coma is an independent risk factor 1.

Common Pitfalls to Avoid

1. Routine prophylactic antipsychotics: Do not use haloperidol or atypical antipsychotics to prevent delirium—they are ineffective 1
2. Treating delirium as a primary target with medications: No medication treats delirium itself; they only manage distressing symptoms 2, 4, 5
3. Prolonged antipsychotic use: If used, taper and discontinue as soon as symptoms resolve 2, 6
4. Ignoring underlying causes: Always investigate and treat precipitating medical factors 6
5. Overlooking hypoactive delirium: This subtype is frequently missed but carries similar poor outcomes 7, 6

Family Education and Support

Provide written information about delirium pre-emptively, especially if the patient's condition is declining. Supplement with educational and psychological support from trained staff if delirium develops 3. Family involvement in nonpharmacologic interventions can be beneficial 2.

Monitoring and Follow-up

Use validated screening tools routinely (CAM-ICU or ICDSC in ICU settings) 1. Arrange cognitive screening follow-up after discharge, as delirium is associated with long-term cognitive impairment 1, 6.

The evidence consistently shows that prevention through multicomponent nonpharmacologic bundles is far more effective than any pharmacologic treatment approach 2, 5, 8. When medications are necessary for symptom management, use the lowest effective dose for the shortest possible duration, recognizing that they do not treat the underlying delirium 3, 4.